T. Rowe Price Associates’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $74.9M | Buy |
1,318,616
+913,811
| +226% | +$40.5M | 0.01% | 766 |
|
|
2026
Q1 | $12M | Buy |
404,805
+9,961
| +3% | +$298K | ﹤0.01% | 1172 |
|
|
2025
Q4 | $15.1M | Buy |
394,844
+315,400
| +397% | +$10.3M | ﹤0.01% | 1132 |
|
|
2025
Q3 | $1.9M | Buy |
79,444
+8,072
| +11% | +$152K | ﹤0.01% | 1754 |
|
|
2025
Q2 | $1.06M | Buy |
71,372
+18,063
| +34% | +$299K | ﹤0.01% | 1966 |
|
|
2025
Q1 | $956K | Buy |
53,309
+13,705
| +35% | +$278K | ﹤0.01% | 1981 |
|
|
2024
Q4 | $690K | Sell |
39,604
-241,745
| -86% | -$4.28M | ﹤0.01% | 2140 |
|
|
2024
Q3 | $3.94M | Buy |
281,349
+247,908
| +741% | +$2.58M | ﹤0.01% | 1374 |
|
|
2024
Q2 | $275K | Buy |
33,441
+2,432
| +8% | +$16.4K | ﹤0.01% | 2456 |
|
|
2024
Q1 | $240K | Buy |
31,009
+2,948
| +11% | +$24.9K | ﹤0.01% | 2536 |
|
|
2023
Q4 | $253K | Buy |
28,061
+1,229
| +5% | +$8.95K | ﹤0.01% | 2449 |
|
|
2023
Q3 | $240K | Sell |
26,832
-10,319
| -28% | -$146K | ﹤0.01% | 2436 |
|
|
2023
Q2 | $571K | Buy |
37,151
+5,861
| +19% | +$107K | ﹤0.01% | 2061 |
|
|
2023
Q1 | $704K | Buy |
31,290
+2,292
| +8% | +$48.7K | ﹤0.01% | 1959 |
|
|
2022
Q4 | $610K | Sell |
28,998
-1,976
| -6% | -$41.9K | ﹤0.01% | 2043 |
|
|
2022
Q3 | $764K | Buy |
30,974
+4,106
| +15% | +$106K | ﹤0.01% | 1902 |
|
|
2022
Q2 | $651K | Buy |
26,868
+10,382
| +63% | +$261K | ﹤0.01% | 2100 |
|
|
2022
Q1 | $425K | Buy |
16,486
+2,289
| +16% | +$60.8K | ﹤0.01% | 2411 |
|
|
2021
Q4 | $441K | Buy |
+14,197
| New | +$400K | ﹤0.01% | 2447 |
|
|
2018
Q1 | – | Sell |
-286,201
| Closed | -$6.03M | – | 2583 |
|
|
2017
Q4 | $6.03M | Sell |
286,201
-60,500
| -17% | -$1.38M | ﹤0.01% | 1412 |
|
|
2017
Q3 | $8.63M | Buy |
346,701
+1,907
| +0.6% | +$42K | ﹤0.01% | 1357 |
|
|
2017
Q2 | $6.69M | Sell |
344,794
-155,616
| -31% | -$2.82M | ﹤0.01% | 1376 |
|
|
2017
Q1 | $9.24M | Sell |
500,410
-136,900
| -21% | -$2.68M | ﹤0.01% | 1347 |
|
|
2016
Q4 | $12.1M | Sell |
637,310
-211,560
| -25% | -$4.33M | ﹤0.01% | 1278 |
|
|
2016
Q3 | $19M | Buy |
848,870
+140,181
| +20% | +$2.67M | ﹤0.01% | 1151 |
|
|
2016
Q2 | $12.6M | Sell |
708,689
-15,100
| -2% | -$244K | ﹤0.01% | 1244 |
|
|
2016
Q1 | $9.89M | Buy |
723,789
+5,700
| +0.8% | +$86.5K | ﹤0.01% | 1274 |
|
|
2015
Q4 | $13.9M | Sell |
718,089
-2,000
| -0.3% | -$40K | ﹤0.01% | 1200 |
|
|
2015
Q3 | $14.6M | Sell |
720,089
-27,111
| -4% | -$803K | ﹤0.01% | 1199 |
|
|
2015
Q2 | $24.8M | Hold |
747,200
| – | – | 0.01% | 1071 |
|
|
2015
Q1 | $17.9M | Buy |
+747,200
| New | +$11.4M | ﹤0.01% | 1168 |
|
Other funds holding TVTX
JT
PA
NAMI
T. Rowe Price Associates's TVTX Position: Q2 2026 in Review
T. Rowe Price Associates increased its Travere Therapeutics (TVTX) stake by 226% in Q2 2026, buying an estimated $40.5M and bringing the position to 1,318,616 shares worth $74.9M. The position accounts for 0.01% of the portfolio, ranked #766.
T. Rowe Price Associates first reported a position in TVTX in Q1 2015 and has held it in 31 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.
- T. Rowe Price Associates held 1,318,616 shares of Travere Therapeutics worth $74.9M as of Q2 2026.
- T. Rowe Price Associates bought 913,811 Travere Therapeutics shares in Q2 2026, an estimated $40.5M.
- Travere Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #766 holding.
- T. Rowe Price Associates first reported a position in Travere Therapeutics in Q1 2015 and has held it in 31 quarters since.
- 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.